• Gabrielė Plungytė LSMU MA Šeimos medicinos klinika
  • Kamilė Žilinskienė LSMU MA Šeimos medicinos klinika
  • Jolanta Sauserienė LSMU MA Šeimos medicinos klinika
  • Leonas Valius LSMU MA Šeimos medicinos klinika
Keywords: adverse reactions after COVID–19 vaccination, COVID–19 vaccination, Comirnaty vaccine


The rate of development of the COVID–19 vaccine is an unprecedented phenomenon in medical history [7, 8]. Adverse reactions, their frequency and severity are the subject of much debate, both in clinical trials and at the start of vaccination in at–risk individuals. Cases of serious health problems associated with vaccines are widely analysed in the media, increasing public fear of vaccination, and official statistics on adverse reactions to vaccines registered in Lithuania may not be accurate due to inconveniences of registration. In this context, research data from real clinical practice is becoming extremely important for GPs, which would allow them to anticipate possible adverse reactions in patients and to manage them effectively. Aim of the study. To identify adverse reactions and the circumstances of their occurrence after COVID–19 vaccination. Objectives of the study. 1. To determine the time and intensity of adverse reactions to COVID–19 vaccine. 2. To evaluate the impact of adverse reactions on workability. Methodology. The study was performed at the Hospital of Lithuanian University of Health Sciences Kauno klinikos temporarily established COVID–19 vaccination centre in February to March 2021. Study participants, adults who received a second dose of the vaccine, were informed of the purpose and course of the study and voluntarily completed an anonymous questionnaire about adverse reactions after the first dose of the vaccine. The questionnaire consisted of 20 different types of questions and presented scales for the evaluation of adverse reactions with scores from 1 (mild) to 5 (very severe). Statistical analysis was performed using SPSS 26.0 for Windows data processing package. Results and conclusions. 1. Out of a total of 4344 respondents, 2305 (53.1%) symptoms occurred after vaccination, of which 19.2% were men and 80.8% were women. 2. The highest number of adverse events following COVID–19 vaccination was reported in subjects aged 25–34 years, of which 46.3% were men. The least adverse events were observed in subjects ≥65 years of age. 3. No acute allergic reaction to the vaccine was observed after the first dose of COVID–19, and 4.8% of patients reported treatment for certain post–vaccination symptoms. 4. The most common symptom is injection site pain, which occurred in 94.4% of subjects who experienced adverse reactions. Cough, dyspnoea, diarrhoea, loss of taste and smell were uncommon (≤1%). 5. Of the 2305 subjects who experienced post–vaccination adverse reactions, 265 were sick and women were statistically significantly less able to work than men. This study, the first large–scale scientific adverse reaction to COVID–19 vaccine in Lithuania, revealed that adverse reactions are common, but usually mild and transient, rarely interrupting short–term function or requiring short–term medical treatment to control adverse symptoms.